Globe Newswire05.16.18
American CryoStem Corporation, a strategic application developer, marketer, global licensor of patented adipose tissue-based cellular technologies for the regenerative and personalized medicine industries, has further expanded its global laboratory and cellular technology footprint by entering into an agreement to license its ATGRAFT and ATCELL adipose tissue (fat) processing and storage technologies with Cryoviva (Thailand) Ltd., a Bangkok, Thailand-based cord blood processing and storage facility. Cryoviva currently offers collection, processing and storage of cord blood-derived biologics to patients throughout Thailand and Southeast Asia.
American CryoStem has licensed to Cryoviva (Thailand) Ltd., established in 2007, the rights to utilize the company's standard operating procedures (SOPs) to create and market the company's ATGRAFT tissue storage service and ATCELL adipose-derived stem cell processing and storage services in Thailand. The financial terms generally, call for the payment of certain training fees and, a percentage of the gross revenue subject to annual minimum payments generated from our products. Additionally, the agreement calls for the purchase of CRYO consumable products required for ATGRAFT and ATCELL sample processing including CRYO's ACSelerate non-DMSO cryogenic tissue storage media, transportation media, Cellect tissue collection kit, and ACSelerate – Max cell culture medium.
John Arnone, CEO of American CryoStem commented, "We are pleased to announce our fourth international licensing agreement in the Asian market for our collect-process-store-retrieve, adipose tissue and cellular based platform with an established company of Cryoviva’s caliber and global presence. This license furthers our corporate mission to establish a global network of laboratories operating under a standardized platform utilizing our patented consumables for processing. Working with Cryoviva in the Thailand market presents an exciting opportunity for our technology to provide the foundational tissue processing and cryopreservation support platform required for the advancement of the rapidly expanding regenerative/personalized medicine and cell therapy market. Further, we also gain another experienced affiliate as we work our way through U.S. FDA and continue to develop adipose derived cellular applications.”
Anthony Dudzinski, chief operating officer of American CryoStem, added, "American CryoStem's entry into the Thailand market represents an extension of the company's ongoing licensing and product distribution efforts into new markets. This licensing agreement allows our partners to grow and establish a foundation in the adipose tissue-derived cellular therapy market, while also providing the opportunity to leverage our full multi-phase adipose tissue and stem cell solution. This includes expansion, differentiation and return methods, as well as the materials to create a true 'point of care' platform. As Thailand and the greater Asian regenerative market continue to grow, we expect increasing distribution of our products and services."
American CryoStem Corporation, founded in 2008, is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies (adult stem cells) for the fields of regenerative and personalized medicine. The company operates a state-of-art, U.S. Food and Drug Administration-registered, laboratory in New Jersey and licensed laboratories in Hong Kong; Bangkok, Thailand; China; and Tokyo, Japan; which operate on a proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose-derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds proprietary technology which supports a growing pipeline of stem cell applications and biologic products. The company leverages its platform and a developed product portfolio to create a global footprint of licensed laboratory affiliates, domestic and international physicians networks and research organizations who purchase tissue collection, processing and storage consumables from CRYO. Its laboratory stem cell bank/line products are characterized adult human mesenchymal stem cell (MSCs) derived from adipose tissue that work in conjunction with our patented (non-animal) medium lines. The company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
Cryoviva (Thailand) Ltd. was established in 2007 with the cooperation of companies such as Indorama Ventures Public Company Limited Thailand, Chelyabins International India, and Arjun Corp India, a company specializing in stem cells. Cryoviva has been certified to ISO 9001: 2008 standards and Laboratory Management System standards according to ISO 15189: 2007, and is also the only cord blood bank certified by AABB. Cryoviva (Thailand) Co., Ltd. is the only stem cell bank that has been approved by the Board of Investment.
American CryoStem has licensed to Cryoviva (Thailand) Ltd., established in 2007, the rights to utilize the company's standard operating procedures (SOPs) to create and market the company's ATGRAFT tissue storage service and ATCELL adipose-derived stem cell processing and storage services in Thailand. The financial terms generally, call for the payment of certain training fees and, a percentage of the gross revenue subject to annual minimum payments generated from our products. Additionally, the agreement calls for the purchase of CRYO consumable products required for ATGRAFT and ATCELL sample processing including CRYO's ACSelerate non-DMSO cryogenic tissue storage media, transportation media, Cellect tissue collection kit, and ACSelerate – Max cell culture medium.
John Arnone, CEO of American CryoStem commented, "We are pleased to announce our fourth international licensing agreement in the Asian market for our collect-process-store-retrieve, adipose tissue and cellular based platform with an established company of Cryoviva’s caliber and global presence. This license furthers our corporate mission to establish a global network of laboratories operating under a standardized platform utilizing our patented consumables for processing. Working with Cryoviva in the Thailand market presents an exciting opportunity for our technology to provide the foundational tissue processing and cryopreservation support platform required for the advancement of the rapidly expanding regenerative/personalized medicine and cell therapy market. Further, we also gain another experienced affiliate as we work our way through U.S. FDA and continue to develop adipose derived cellular applications.”
Anthony Dudzinski, chief operating officer of American CryoStem, added, "American CryoStem's entry into the Thailand market represents an extension of the company's ongoing licensing and product distribution efforts into new markets. This licensing agreement allows our partners to grow and establish a foundation in the adipose tissue-derived cellular therapy market, while also providing the opportunity to leverage our full multi-phase adipose tissue and stem cell solution. This includes expansion, differentiation and return methods, as well as the materials to create a true 'point of care' platform. As Thailand and the greater Asian regenerative market continue to grow, we expect increasing distribution of our products and services."
American CryoStem Corporation, founded in 2008, is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies (adult stem cells) for the fields of regenerative and personalized medicine. The company operates a state-of-art, U.S. Food and Drug Administration-registered, laboratory in New Jersey and licensed laboratories in Hong Kong; Bangkok, Thailand; China; and Tokyo, Japan; which operate on a proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose-derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds proprietary technology which supports a growing pipeline of stem cell applications and biologic products. The company leverages its platform and a developed product portfolio to create a global footprint of licensed laboratory affiliates, domestic and international physicians networks and research organizations who purchase tissue collection, processing and storage consumables from CRYO. Its laboratory stem cell bank/line products are characterized adult human mesenchymal stem cell (MSCs) derived from adipose tissue that work in conjunction with our patented (non-animal) medium lines. The company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
Cryoviva (Thailand) Ltd. was established in 2007 with the cooperation of companies such as Indorama Ventures Public Company Limited Thailand, Chelyabins International India, and Arjun Corp India, a company specializing in stem cells. Cryoviva has been certified to ISO 9001: 2008 standards and Laboratory Management System standards according to ISO 15189: 2007, and is also the only cord blood bank certified by AABB. Cryoviva (Thailand) Co., Ltd. is the only stem cell bank that has been approved by the Board of Investment.
